[go: up one dir, main page]

GR3031514T3 - USE OF ANTAGONISTS OR PARTIAL AGONISTS ON THE 5-HT 1a RECEPTOR FOR THE TREATMENT AND PREVENTION OF COGNITIVE DISORDERS - Google Patents

USE OF ANTAGONISTS OR PARTIAL AGONISTS ON THE 5-HT 1a RECEPTOR FOR THE TREATMENT AND PREVENTION OF COGNITIVE DISORDERS

Info

Publication number
GR3031514T3
GR3031514T3 GR990402609T GR990402609T GR3031514T3 GR 3031514 T3 GR3031514 T3 GR 3031514T3 GR 990402609 T GR990402609 T GR 990402609T GR 990402609 T GR990402609 T GR 990402609T GR 3031514 T3 GR3031514 T3 GR 3031514T3
Authority
GR
Greece
Prior art keywords
antagonists
receptor
prevention
treatment
partial agonists
Prior art date
Application number
GR990402609T
Other languages
English (en)
Inventor
Jonathan Turner
Belinda Cole
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6443608&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GR3031514(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of GR3031514T3 publication Critical patent/GR3031514T3/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
GR990402609T 1991-08-31 1999-10-13 USE OF ANTAGONISTS OR PARTIAL AGONISTS ON THE 5-HT 1a RECEPTOR FOR THE TREATMENT AND PREVENTION OF COGNITIVE DISORDERS GR3031514T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4135551A DE4135551A1 (de) 1991-08-31 1991-08-31 Verwendung von antagonisten oder partiellen agonisten am 5-ht1a-rezeptor zur behandlung und praevention von kognitiven stoerungen
PCT/DE1992/000720 WO1993004681A1 (de) 1991-08-31 1992-08-28 VERWENDUNG VON ANTAGONISTEN ODER PARTIELLEN AGONISTEN AM 5-HT1a-REZEPTOR ZUR BEHANDLUNG UND PRÄVENTION VON KOGNITIVEN STÖRUNGEN

Publications (1)

Publication Number Publication Date
GR3031514T3 true GR3031514T3 (en) 2000-01-31

Family

ID=6443608

Family Applications (1)

Application Number Title Priority Date Filing Date
GR990402609T GR3031514T3 (en) 1991-08-31 1999-10-13 USE OF ANTAGONISTS OR PARTIAL AGONISTS ON THE 5-HT 1a RECEPTOR FOR THE TREATMENT AND PREVENTION OF COGNITIVE DISORDERS

Country Status (10)

Country Link
EP (1) EP0555446B1 (el)
JP (1) JPH06501713A (el)
AT (1) ATE182467T1 (el)
CA (1) CA2093009A1 (el)
DE (2) DE4135551A1 (el)
DK (1) DK0555446T3 (el)
ES (1) ES2135412T3 (el)
GR (1) GR3031514T3 (el)
HU (1) HUT63331A (el)
WO (1) WO1993004681A1 (el)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9223153D0 (en) * 1992-11-05 1992-12-16 Wyeth John & Brother Ltd Piperazine derivatives
US5484788A (en) * 1993-03-26 1996-01-16 Beth Israel Hospital Association Buspirone as a systemic immunosuppressant
EP0710481A1 (en) * 1994-11-02 1996-05-08 Duphar International Research B.V Use of flesinoxan for cognition enhancement
US5637314A (en) * 1995-06-07 1997-06-10 Beth Israel Deaconess Medical Center, Inc. Topical and systemic application of buspirone or derivatives thereof for treating atopic dermatitis
WO1999057131A1 (en) 1998-05-06 1999-11-11 Duke University Method of treating bladder and lower urinary tract syndromes
US7053092B2 (en) 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
US8703772B2 (en) 2001-09-25 2014-04-22 Otsuka Pharmaceutical Co., Ltd. Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
GT200600414A (es) 2005-09-12 2007-09-20 Sal de glucuranato de compuesto de piperazine
PE20070523A1 (es) 2005-09-12 2007-06-28 Wyeth Corp Formulacion de liberacion sostenida del glucuronato de (8-{4-[3-(5-fluoro-1h-indol-3-il)-propil]-piperazin-1-il}-2-metil-4h-benzo[1,4]oxazin-3-ona
GT200600416A (es) 2005-09-12 2007-09-20 Sales salicilato y gentisato de un compuesto de piperazina
CN102918031A (zh) 2010-05-28 2013-02-06 通用电气健康护理有限公司 放射标记的化合物及其方法
GB201112987D0 (en) 2011-07-28 2011-09-14 Ge Healthcare Ltd Novel compound

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2355502A1 (fr) * 1976-06-23 1978-01-20 Roussel Uclaf Application a titre de medicaments d'un derive de la piperazine et de ses sels
US4423049A (en) * 1981-12-28 1983-12-27 Mead Johnson & Company 2-[4-[(4,4-Dialkyl-2,6-piperidinedion-1-yl)butyl]-1-piperazinyl]pyrimidines
US4897399A (en) * 1988-04-20 1990-01-30 Ciba-Geigy Corp. Heterotertracyclic lactam derivatives, pharmaceutical compositions, and method of treating impaired memory and learning
GB2222768B (en) * 1988-06-17 1992-01-22 Nat Res Dev Analgesic compounds and compositions
US4902687A (en) * 1989-03-27 1990-02-20 Eli Lilly And Company Excitatory amino acid receptor antagonists
DE4039631A1 (de) * 1990-12-12 1992-06-17 Troponwerke Gmbh & Co Kg Neuroprotektive kombination

Also Published As

Publication number Publication date
JPH06501713A (ja) 1994-02-24
ES2135412T3 (es) 1999-11-01
EP0555446B1 (de) 1999-07-28
HUT63331A (en) 1993-08-30
DE4135551A1 (de) 1993-03-04
DE59209728D1 (de) 1999-09-02
HU9301250D0 (en) 1993-07-28
EP0555446A1 (de) 1993-08-18
DK0555446T3 (da) 2000-01-31
CA2093009A1 (en) 1993-03-01
WO1993004681A1 (de) 1993-03-18
ATE182467T1 (de) 1999-08-15

Similar Documents

Publication Publication Date Title
CY2123B1 (en) Isoxazole-4-carboxamides and hydroxyalkylidene-cyanoacetamides drugs containing these compounds and use of such drugs
MY110110A (en) Pharmaceuticals in the treatment of gastrointestinal disorders, cardiovascular disorders and cns disorders
GR3031514T3 (en) USE OF ANTAGONISTS OR PARTIAL AGONISTS ON THE 5-HT 1a RECEPTOR FOR THE TREATMENT AND PREVENTION OF COGNITIVE DISORDERS
GB9514473D0 (en) Chemical compounds
AU6226494A (en) Spiroazacyclic derivatives as substance p antagonists
SG52320A1 (en) Novel (R)-5-carbamoyl-8-fluoro-3-N,N-disubstituted-amino-3,4-dihydro-2H-1-benzopyrans
ZA946142B (en) Therapeutic heterocycles
MY111201A (en) New imidazopyridines
AU3745795A (en) Use of CCK-B receptor antagonists for the treatment of sleepdisorders
EP0551963A3 (en) Use of heterocyclic derivatives for the manufacture of medicaments
GB8518658D0 (en) Medicaments
GB9212308D0 (en) Therapeutic compositions
IL86077A0 (en) Receptor of the small rhinovirus receptor group,its preparation and pharmaceutical compositions containing it
AU655958B2 (en) Use of quisqualate-receptor antagonists for treating Parkinson's disease
MX9708557A (es) Nuevo uso farmacologico de los antagonistas del receptor aii.
IL109076A0 (en) Imidazolo-quinoxalinones, their preparation and pharmaceutical compositions containing them
AU2884489A (en) Compounds with a psychotropic action, agents containing them, and the use thereof for the treatment and prophylaxis of disorders of the central nervous system
AU5627194A (en) New use of 5-ht3 receptor antagonists
IT1296613B1 (it) Farmaco per la cura dell'ircismo contenente un adrenocorticosteroide.
ES2000369A6 (es) Un procedimiento para preparar di-t-butilfenoles sustituidos
DE3778165D1 (el)
ES2013391A6 (es) Procedimiento para la preparacion de derivados acetilenicos y alenicos de 2-aminometil -5-metoxiindoles.
ZA89574B (en) Compounds with a psychotropic action,agents containing them,and the use thereof for the treatment and prophylaxis of disorders of the central nervous system
ES2065238A1 (es) Derivados de benceno condensados con actividad antagonista del receptor 5-ht4, procedimiento para su preparacion, composiciones que los contienen y aplicaciones.
ZA903015B (en) Therapeutic use of 5-ht3 receptor antagonists